

considered related to atogepant. AEs reported by $\geq 5\%$ of atogepant-treated participants were upper respiratory tract infection (10.3%), constipation (7.2%), nausea (6.3%), and urinary tract infection (5.2%). 4.4% of atogepant participants reported serious AEs that included various, common medical conditions; no event occurred in ≥ 1 participant and none were atogepant-related. Two deaths were reported in atogepant-treated participants (homicide victim; toxic shock syndrome); both were considered not treatment-related. 5.7% of atogepant participants discontinued due to AEs. Alanine aminotransferase/aspartate aminotransferase levels $\geq 3X$ upper limit of normal were reported for 2.4% of atogepant participants ($n=13/531$) and 3.2% of SOC participants ($n=6/190$). No cases of potential Hy's Law were reported. **Conclusions:** Once-daily use of atogepant for preventive treatment of migraine over 1 year was safe and well-tolerated with no safety concerns identified.

P.031

A Rare Canadian Case of Cervical Pyomyositis Presenting as Occipital Neuralgia

H Girgis (Ottawa), M Ziller (Montreal)*

doi: 10.1017/cjn.2021.313

Background: Pyomyositis is an infectious disease usually encountered in tropical regions. It typically occurs in immunocompromised hosts and most commonly affects lower limb muscles. Our patient was a healthy Canadian with an atypical presentation of cervical pyomyositis. **Methods:** We report a case of a healthy 22-year old woman presenting to the emergency department with unprovoked severe bilateral cervico-occipital pain and nuchal rigidity. She remained afebrile. Review of the literature was conducted to search for similar presentations. **Results:** A Computed Tomography scan of the head and neck demonstrated the presence of a ring enhancing lesion in the semispinalis capitis muscle extending from the occiput to the C4 level. The abscess was surgically drained and cultures grew staphylococcus aureus. The patient rapidly improved on intravenous antibiotics. Literature review revealed this to be the first Canadian case of cervical pyomyositis. **Conclusions:** Cervical pyomyositis can be complicated by local destruction of the vertebrae, septic shock, endocarditis, septic emboli, brain abscess or rhabdomyolysis. Early diagnosis and source control is necessary to reduce the risk of morbidity. Therefore, it is important to consider this rare disease in the differential diagnosis of cervicgia even in healthy immunocompetent patients.

P.032

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial

D Kudrow (Santa Monica) R Cady (Bothell) B Allan (Bothell) S Pederson (Bothell) J Hirman (Woodinville) M Meessen-Pinard (Montreal), B Schaeffler (Bothell)*

doi: 10.1017/cjn.2021.314

Background: Eptinezumab is approved in the US for the preventive treatment of migraine and was well tolerated in

double-blind, placebo-controlled studies in patients with episodic and chronic migraine (CM). The PREVAIL study evaluated the long-term safety, immunogenicity, and impact on patient-reported outcomes of repeat doses of eptinezumab in patients with CM. **Methods:** PREVAIL was an open-label, phase 3 trial comprising two 48-week treatment phases. Adults with CM received eptinezumab 300 mg by 30-minute IV every 12 weeks for ≤ 8 doses, with patients followed up to week 104. **Results:** 128 adults (mean age, 41.5y) with CM were treated. Over 2 years, the most frequently reported treatment-emergent adverse events were nasopharyngitis (14.1%), upper respiratory tract infection (7.8%), sinusitis (7.8%), influenza (6.3%), bronchitis (5.5%), and migraine (5.5%). Study-drug discontinuation due to adverse events was 6.3%. Anti-eptinezumab antibody incidence peaked at week 24 and declined despite continued dosing, to nondetectable levels at week 104. Patient-reported outcomes were improved at first assessment (week 4) and generally sustained through week 104. **Conclusions:** In adults with CM, eptinezumab 300 mg demonstrated a favorable safety profile, limited long-term immunogenicity, early and sustained reductions in migraine-related burden, and improvements in health-related quality of life over 2 years.

P.033

Eptinezumab reduced acute medication use in patients with chronic migraine and medication-overuse headache: subgroup analysis of Promise-2

MJ Marmura (Philadelphia) H Diener (Essen) J Hirman (Woodinville) R Cady (Bothell) T Brevig (Copenhagen) E Brunner (Deerfield) S Minhas (Montreal), L Mehta (Copenhagen)*

doi: 10.1017/cjn.2021.315

Background: Eptinezumab is a preventive migraine treatment approved in the US. We evaluated the impact of eptinezumab on acute headache medication (AHM) use in patients diagnosed with chronic migraine (CM) and medication-overuse headache (MOH) in PROMISE-2. **Methods:** PROMISE-2 randomized patients with CM to eptinezumab 100mg, 300mg, or placebo for 2 intravenous doses administered every 12 weeks. Trained investigators diagnosed MOH at screening using 3-month medication history and ICHD-3b criteria. Endpoints included days/month of any AHM use (days of ≥ 1 medication class), total AHM use (summed days for each medication class), and triptan use over Weeks 1-12 and 13-24. AHM classes included triptan, ergot, opioid, simple analgesic, and combination analgesic. **Results:** Of 1072 PROMISE-2 patients, 431 (40.2%) were diagnosed with MOH (100mg, $n=139$; 300mg, $n=147$; placebo, $n=145$). During the 28-day baseline period, mean days of any AHM was ~ 16.4 , total AHM was ~ 20.4 , and triptan was ~ 8.9 across treatment arms. Over Weeks 1-12, mean days/month of any AHM was 8.8 (100mg), 9.9 (300mg), and 11.8 (placebo); total AHM was 10.8, 12.2, and 14.8; triptan was 4.3, 4.4, and 6.4. Similar or lower rates were observed over Weeks 13-24. **Conclusions:** In patients diagnosed with both CM and MOH, eptinezumab treatment reduced AHM use.